Inflammatory bowel disease (IBD) is a group of chronic relapsing inflammatory disorders affecting the large and small intestine, with a rising worldwide incidence and prevalence. Anaemia is the most common extraintestinal manifestation of IBD, correlating with disease activity, and tending to relapse even after successful therapy. Iron deficiency is the most common cause; however, it often manifests in combination with anaemia of inflammation. As such, multiple parameters are used for the diagnosis of iron deficiency anaemia in IBD. Timely recognition and selection of appropriate therapy leads to an improvement in the quality of life and prevention of potential sequelae. Oral iron can be effective under specific circumstances; however, as luminal iron changes microbiota and bacterial metabolism, oral administration should be avoided. Intravenous iron is preferred as it bypasses the sites of inflammation. Nevertheless, the optimization of IBD treatment should occur simultaneously, as this improves both patient condition and response to iron therapy. Herein, we discuss the screening, diagnosis, selection of therapy, and follow-up for iron deficiency anaemia in IBD.

1.
Ng
SC
,
Shi
HY
,
Hamidi
N
,
Underwood
FE
,
Tang
W
,
Benchimol
EI
, et al.
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
.
Lancet
.
2018
Dec
;
390
(
10114
):
2769
78
.
[PubMed]
0140-6736
2.
Filmann
N
,
Rey
J
,
Schneeweiss
S
,
Ardizzone
S
,
Bager
P
,
Bergamaschi
G
, et al.
Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis
.
Inflamm Bowel Dis
.
2014
May
;
20
(
5
):
936
45
.
[PubMed]
1078-0998
3.
Weiss
G
.
Anemia of chronic disorders: new diagnostic tools and new treatment strategies
.
Semin Hematol
.
2015
Oct
;
52
(
4
):
313
20
.
[PubMed]
0037-1963
4.
Evstatiev
R
,
Gasche
C
.
Iron sensing and signalling
.
Gut
.
2012
Jun
;
61
(
6
):
933
52
.
[PubMed]
0017-5749
5.
Dignass
AU
,
Gasche
C
,
Bettenworth
D
,
Birgegard
G
,
Danese
S
,
Gisbert
JP
, et al.;
European Cs
.
Colitis O: european consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases
.
J Crohn’s Colitis
.
2014
.1873-9946
6.
World Health Organization CfDCaP
.
Assessing the iron status of populations
. 2nd ed.
Geneva, Switzerland
;
2007
.
7.
Beutler
E
,
Waalen
J
.
The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?
Blood
.
2006
Mar
;
107
(
5
):
1747
50
.
[PubMed]
0006-4971
8.
Cook
JD
,
Boy
E
,
Flowers
C
,
Daroca
MC
.
The influence of high-altitude living on body iron
.
Blood
.
2005
Aug
;
106
(
4
):
1441
6
.
[PubMed]
0006-4971
9.
Oustamanolakis
P
,
Koutroubakis
IE
,
Messaritakis
I
,
Kefalogiannis
G
,
Niniraki
M
,
Kouroumalis
EA
.
Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease
.
J Crohn’s Colitis
.
2011
Aug
;
5
(
4
):
295
300
.
[PubMed]
1873-9946
10.
Evstatiev
R
,
Marteau
P
,
Iqbal
T
,
Khalif
IL
,
Stein
J
,
Bokemeyer
B
,
Chopey
IV
,
Gutzwiller
FS
,
Riopel
L
,
Gasche
C
,
Group
FS
:
Fergicor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
Gastroenterology
2011
;141:846-853 e841-842.
11.
Gisbert
JP
,
Bermejo
F
,
Pajares
R
,
Pérez-Calle
JL
,
Rodríguez
M
,
Algaba
A
, et al.
Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement
.
Inflamm Bowel Dis
.
2009
Oct
;
15
(
10
):
1485
91
.
[PubMed]
1078-0998
12.
Wells
CW
,
Lewis
S
,
Barton
JR
,
Corbett
S
.
Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients
.
Inflamm Bowel Dis
.
2006
Feb
;
12
(
2
):
123
30
.
[PubMed]
1078-0998
13.
Bruner
AB
,
Joffe
A
,
Duggan
AK
,
Casella
JF
,
Brandt
J
.
Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls
.
Lancet
.
1996
Oct
;
348
(
9033
):
992
6
.
[PubMed]
0140-6736
14.
Wang
J
,
O’Reilly
B
,
Venkataraman
R
,
Mysliwiec
V
,
Mysliwiec
A
.
Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study
.
Sleep Med
.
2009
Oct
;
10
(
9
):
973
5
.
[PubMed]
1389-9457
15.
Krayenbuehl
PA
,
Battegay
E
,
Breymann
C
,
Furrer
J
,
Schulthess
G
.
Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration
.
Blood
.
2011
Sep
;
118
(
12
):
3222
7
.
[PubMed]
0006-4971
16.
González Alayón
C
,
Pedrajas Crespo
C
,
Marín Pedrosa
S
,
Benítez
JM
,
Iglesias Flores
E
,
Salgueiro Rodríguez
I
, et al.
Prevalence of iron deficiency without anaemia in inflammatory bowel disease and impact on health-related quality of life
.
Gastroenterol Hepatol
.
2018
Jan
;
41
(
1
):
22
9
.
[PubMed]
0210-5705
17.
Gasche
C
,
Waldhoer
T
,
Feichtenschlager
T
,
Male
C
,
Mayer
A
,
Mittermaier
C
, et al.;
Austrian Inflammatory Bowel Diseases Study Group
.
Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia
.
Am J Gastroenterol
.
2001
Aug
;
96
(
8
):
2382
7
.
[PubMed]
0002-9270
18.
Lee
T
,
Clavel
T
,
Smirnov
K
,
Schmidt
A
,
Lagkouvardos
I
,
Walker
A
, et al.
Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD
.
Gut
.
2017
May
;
66
(
5
):
863
71
.
[PubMed]
0017-5749
19.
Zimmermann
MB
,
Chassard
C
,
Rohner
F
,
N’goran
EK
,
Nindjin
C
,
Dostal
A
, et al.
The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d’Ivoire
.
Am J Clin Nutr
.
2010
Dec
;
92
(
6
):
1406
15
.
[PubMed]
0002-9165
20.
Mahalhal
A
,
Williams
JM
,
Johnson
S
,
Ellaby
N
,
Duckworth
CA
,
Burkitt
MD
, et al.
Oral iron exacerbates colitis and influences the intestinal microbiome
.
PLoS One
.
2018
Oct
;
13
(
10
):
e0202460
.
[PubMed]
1932-6203
21.
Seril
DN
,
Liao
J
,
Ho
KL
,
Warsi
A
,
Yang
CS
,
Yang
GY
.
Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice
.
Dig Dis Sci
.
2002
Jun
;
47
(
6
):
1266
78
.
[PubMed]
0163-2116
22.
Cancelo-Hidalgo
MJ
,
Castelo-Branco
C
,
Palacios
S
,
Haya-Palazuelos
J
,
Ciria-Recasens
M
,
Manasanch
J
, et al.
Tolerability of different oral iron supplements: a systematic review
.
Curr Med Res Opin
.
2013
Apr
;
29
(
4
):
291
303
.
[PubMed]
0300-7995
23.
Tolkien
Z
,
Stecher
L
,
Mander
AP
,
Pereira
DI
,
Powell
JJ
.
Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis
.
PLoS One
.
2015
Feb
;
10
(
2
):
e0117383
.
[PubMed]
1932-6203
24.
Makrides
M
,
Crowther
CA
,
Gibson
RA
,
Gibson
RS
,
Skeaff
CM
.
Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomized controlled trial
.
Am J Clin Nutr
.
2003
Jul
;
78
(
1
):
145
53
.
[PubMed]
0002-9165
25.
Rimon
E
,
Kagansky
N
,
Kagansky
M
,
Mechnick
L
,
Mashiah
T
,
Namir
M
, et al.
Are we giving too much iron? Low-dose iron therapy is effective in octogenarians
.
Am J Med
.
2005
Oct
;
118
(
10
):
1142
7
.
[PubMed]
0002-9343
26.
Moretti
D
,
Goede
JS
,
Zeder
C
,
Jiskra
M
,
Chatzinakou
V
,
Tjalsma
H
, et al.
Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women
.
Blood
.
2015
Oct
;
126
(
17
):
1981
9
.
[PubMed]
0006-4971
27.
Stoffel
NU
,
Cercamondi
CI
,
Brittenham
G
,
Zeder
C
,
Geurts-Moespot
AJ
,
Swinkels
DW
, et al.
Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials
.
Lancet Haematol
.
2017
Nov
;
4
(
11
):
e524
33
.
[PubMed]
2352-3026
28.
Gasche
C
,
Ahmad
T
,
Tulassay
Z
,
Baumgart
DC
,
Bokemeyer
B
,
Büning
C
, et al.;
AEGIS Study Group
.
Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program
.
Inflamm Bowel Dis
.
2015
Mar
;
21
(
3
):
579
88
.
[PubMed]
1078-0998
29.
Bonovas
S
,
Fiorino
G
,
Allocca
M
,
Lytras
T
,
Tsantes
A
,
Peyrin-Biroulet
L
, et al.
Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials
.
Medicine (Baltimore)
.
2016
Jan
;
95
(
2
):
e2308
.
[PubMed]
0025-7974
30.
Stein
J
,
Haas
JS
,
Ong
SH
,
Borchert
K
,
Hardt
T
,
Lechat
E
, et al.
Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany - a real-world evidence analysis
.
Clinicoecon Outcomes Res
.
2018
Feb
;
10
:
93
103
.
[PubMed]
1178-6981
31.
Akhuemonkhan
E
,
Parian
A
,
Carson
KA
,
Hutfless
S
.
Adverse reactions after intravenous iron infusion among inflammatory bowel disease patients in the united states, 2010-2014
.
Inflamm Bowel Dis
.
2018
Jul
;
24
(
8
):
1801
7
.
[PubMed]
1078-0998
32.
Rampton
D
,
Folkersen
J
,
Fishbane
S
,
Hedenus
M
,
Howaldt
S
,
Locatelli
F
, et al.
Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management
.
Haematologica
.
2014
Nov
;
99
(
11
):
1671
6
.
[PubMed]
0390-6078
33.
Ganzoni
AM
.
[Intravenous iron-dextran: therapeutic and experimental possibilities]
.
Schweiz Med Wochenschr
.
1970
Feb
;
100
(
7
):
301
3
.
[PubMed]
0036-7672
34.
Kulnigg
S
,
Stoinov
S
,
Simanenkov
V
,
Dudar
LV
,
Karnafel
W
,
Garcia
LC
, et al.
A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial
.
Am J Gastroenterol
.
2008
May
;
103
(
5
):
1182
92
.
[PubMed]
0002-9270
35.
Reinisch
W
,
Staun
M
,
Tandon
RK
,
Altorjay
I
,
Thillainayagam
AV
,
Gratzer
C
, et al.
A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)
.
Am J Gastroenterol
.
2013
Dec
;
108
(
12
):
1877
88
.
[PubMed]
0002-9270
36.
European Medicines Agency
: Ema/579491/2013 new recommendations to manage risk of allergic reactions with intravenous iron-containing medicines, 2013,
2018
,
37.
Stein
J
,
Hartmann
F
,
Dignass
AU
.
Diagnosis and management of iron deficiency anemia in patients with IBD
.
Nat Rev Gastroenterol Hepatol
.
2010
Nov
;
7
(
11
):
599
610
.
[PubMed]
1759-5045
38.
Kulnigg
S
,
Teischinger
L
,
Dejaco
C
,
Waldhör
T
,
Gasche
C
.
Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment
.
Am J Gastroenterol
.
2009
Jun
;
104
(
6
):
1460
7
.
[PubMed]
0002-9270
39.
Carson
JL
,
Grossman
BJ
,
Kleinman
S
,
Tinmouth
AT
,
Marques
MB
,
Fung
MK
, et al.;
Clinical Transfusion Medicine Committee of the AABB
.
Red blood cell transfusion: a clinical practice guideline from the AABB*
.
Ann Intern Med
.
2012
Jul
;
157
(
1
):
49
58
.
[PubMed]
0003-4819
40.
Evstatiev
R
,
Alexeeva
O
,
Bokemeyer
B
,
Chopey
I
,
Felder
M
,
Gudehus
M
,
Iqbal
T
,
Khalif
I
,
Marteau
P
,
Stein
J
,
Gasche
C
,
Group
FS
:
Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2013
;11:269-277.
41.
Cúrdia Gonçalves
T
,
Monteiro
S
,
Barbosa
M
,
Moreira
MJ
,
Cotter
J
.
P294 iron-deficiency without anemia in crohn’s disease: what are the predictive factors of recovery?
J Crohn’s Colitis
.
2017
;
11
suppl_1
:
S226
226
. 1873-9946
42.
Dan
K
.
Thrombocytosis in iron deficiency anemia
.
Intern Med
.
2005
Oct
;
44
(
10
):
1025
6
.
[PubMed]
0918-2918
43.
Kulnigg-Dabsch
S
,
Schmid
W
,
Howaldt
S
,
Stein
J
,
Mickisch
O
,
Waldhör
T
, et al.
Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial
.
Inflamm Bowel Dis
.
2013
Jul
;
19
(
8
):
1609
16
.
[PubMed]
1078-0998
44.
Simanek
R
,
Vormittag
R
,
Ay
C
,
Alguel
G
,
Dunkler
D
,
Schwarzinger
I
, et al.
High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
.
J Thromb Haemost
.
2010
Jan
;
8
(
1
):
114
20
.
[PubMed]
1538-7933
45.
Grainge
MJ
,
West
J
,
Card
TR
.
Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study
.
Lancet
.
2010
Feb
;
375
(
9715
):
657
63
.
[PubMed]
0140-6736
46.
Jimenez
K
,
Scharbert
G
,
Leitner
A
,
Schwabl
P
,
Leiter
F
,
Evstatiev
R
, et al.
Pb534 iron deficiency increases platelet procoagulant capacity in a ferric chloride model of arterial thrombosis
.
ISTH
;
2018
.
47.
Anthoni
C
,
Russell
J
,
Wood
KC
,
Stokes
KY
,
Vowinkel
T
,
Kirchhofer
D
, et al.
Tissue factor: a mediator of inflammatory cell recruitment, tissue injury, and thrombus formation in experimental colitis
.
J Exp Med
.
2007
Jul
;
204
(
7
):
1595
601
.
[PubMed]
0022-1007
48.
Carter
PR
,
Watts
MN
,
Kosloski-Davidson
M
,
Prasai
K
,
Grisham
MB
,
Harris
NR
.
Iron status, anemia, and plasma erythropoietin levels in acute and chronic mouse models of colitis
.
Inflamm Bowel Dis
.
2013
May
;
19
(
6
):
1260
5
.
[PubMed]
1078-0998
49.
Ramakrishnan
SK
,
Shah
YM
.
Role of intestinal hif-2alpha in health and disease
.
Annu Rev Physiol
.
2016
;
78
(
1
):
301
25
.
[PubMed]
0066-4278
50.
Jimenez
K
,
Khare
V
,
Evstatiev
R
,
Kulnigg-Dabsch
S
,
Jambrich
M
,
Strobl
H
, et al.
Increased expression of HIF2α during iron deficiency-associated megakaryocytic differentiation
.
J Thromb Haemost
.
2015
Jun
;
13
(
6
):
1113
27
.
[PubMed]
1538-7933
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.